WILLINGTON, England, April 8, 2021 /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz ...

BURTON-ON-TRENT, England--(BUSINESS WIRE)--Clinigen Group plc’s (AIM: CLIN, 'Clinigen') Idis Managed Access division and Sarepta Therapeutics Inc. (NASDAQ: SRPT) have initiated a Managed Access ...

Program designed to fulfill requests from healthcare providers for access to lenzilumab, for patients with unmet medical needs Under the terms of the agreement, Clinigen will manage key elements of ...

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it has entered into an agreement with Idis Managed Access, part of the Clinigen Group plc, to establish a ...

French pharma Onxeo is teaming up with CRO Clinigen to bring blood cancer med belinostat to European patients in dire need through a managed access program. Clinigen’s Idis Managed Access division ...

SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ...

Reinforcing its commitment to rare disease treatment access, Sentynl is transitioning its program to myTomorrows patient-centric platform. AMSTERDAM, Dec. 10, 2025 /PRNewswire/ -- Sentynl Therapeutics ...

(RTTNews) - Humanigen, Inc. (HGEN), Thursday said its antibody, Lenzilumab is now available for certain hospitalized Covid-19 patients through its newly launched Managed Access Program or LenzMAP, ...

* Sarepta Therapeutics and Clinigen launch a managed access program to treat patients with duchenne muscular dystrophy amenable to exon 51 skipping * Sarepta Therapeutics Inc - ‍Sarepta plans to ...

SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ:RNA) announced Wednesday the establishment of a Managed Access Program (MAP) for delpacibart zotadirsen (del-zota), its investigational therapy for ...

Reinforcing its commitment to rare disease treatment access, Sentynl is transitioning its program to myTomorrows patient-centric platform. AMSTERDAM, Dec. 10, 2025 /PRNewswire/ -- Sentynl Therapeutics ...